CABALETTA BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.86 USD | +3.79% |
|
+22.71% | -43.35% |
| Mar. 22 | HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating | MT |
| Mar. 21 | Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Chart calendar Cabaletta Bio, Inc.
8.AKLoNhwbZecuQBV5XVdApL8qCeP1Thn77eZAZHiSMAY.cNW5cF4jKYxsBExIBW4i6o5Hc9fMfle9o4UWFgzhWkE127x_W3QmuGcOdg~a695f054260fbe893d7b5f8e93f43f25
Upcoming events on Cabaletta Bio, Inc.
Past events on Cabaletta Bio, Inc.
| 2024-03-21 07:00 am | Q4 2023 Earnings Release |
| 2024-03-11 | Jefferies Biotech on the Bay Summit |
| 2024-03-05 12:50 pm | TD Cowen Health Care Conference - Fireside Chat |
| 2024-02-07 10:00 am | Guggenheim Healthcare Talks Biotechnology Conference |
| 2024-01-09 08:15 pm | JPMorgan Healthcare Conference |
| 2023-11-29 08:20 am | Evercore ISI HealthCONx Conference |
| 2023-11-14 04:45 pm | Stifel Healthcare Conference |
| 2023-11-09 07:00 am | Q3 2023 Earnings Release |
| 2023-11-06 09:50 am | Guggenheim Securities Inflammation & Immunology Conference |
| 2023-10-10 12:00 am | Cell & Gene Meeting on the Mesa Conference |
| 2023-09-27 08:00 am | Cantor Global Healthcare Conference |
| 2023-09-26 10:30 am | Jefferies Cell & Genetic Medicine Summit |
| 2023-09-13 02:15 pm | Morgan Stanley Global Healthcare Conference |
| 2023-09-13 08:30 am | H.C. Wainwright Global Investment Conference |
| 2023-09-07 01:50 pm | Citi BioPharma Conference |
| 2023-09-05 | Wells Fargo Healthcare Conference |
| 2023-08-10 07:00 am | Q2 2023 Earnings Release |
| 2023-06-07 10:30 am | Jefferies Global Healthcare Conference |
| 2023-06-01 09:00 am | Annual General Meeting |
| 2023-05-19 03:00 pm | American Society of Gene Cell Therapy Meeting - Abstract Number: 1418 |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -18,6 -31,7 41.39% | -33,5 -33,0 -1.58% | -45,5 -62,2 26.84% | -53,2 -52,4 -1.41% | -73,2 -68,5 -6.92% | -95,8 |
|
EBIT Million USD | Released Forecast Spread | -18,7 -25,1 25.49% | -33,8 -33,5 -1.05% | -46,3 -49,8 7.05% | -54,1 -51,8 -4.53% | -74,7 -70,4 -6.09% | -98,5 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -16,9 -22,6 25.03% | -33,3 -32,7 -1.88% | -46,3 -49,7 6.8% | -53,0 -51,1 -3.65% | -67,7 -64,2 -5.35% | -92,4 |
|
Net income Million USD | Released Forecast Spread | -22,3 -22,6 1.46% | -33,3 -32,7 -1.88% | -46,3 -49,7 6.8% | -53,0 -51,1 -3.65% | -67,7 -64,2 -5.37% | -92,4 |
|
EPS USD | Released Forecast Spread | -4,07 -8,48 52% | -1,44 -1,39 -3.41% | -1,80 -1,88 4.17% | -1,81 -1,72 -5.44% | -1,65 -1,59 -3.99% | -1,89 |
| Announcement Date | 30/03/20 | 16/03/21 | 17/03/22 | 16/03/23 | 21/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -22,8 -18,9 -20.56% | -23,3 | -24,1 | -25,1 | -26,1 | |||||||||
|
EBIT Million USD | Released Forecast Spread | -13,9 -14,9 6.79% | -13,0 -15,1 13.96% | -13,1 -14,9 12.53% | -11,8 -13,9 15.54% | -16,3 -13,7 -19.43% | -17,0 -15,7 -8.33% | -15,9 -17,2 7.61% | -18,7 -17,7 -5.33% | -23,1 -19,2 -20.84% | -23,0 | -24,1 | -25,3 | -26,4 | |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -13,9 -14,9 6.83% | -12,9 -15,1 14.31% | -12,9 -14,9 13.54% | -11,4 -13,9 17.67% | -15,7 -13,5 -16.67% | -15,9 -15,3 -3.75% | -14,5 -16,6 12.96% | -16,4 -17,0 3.12% | -20,9 -17,6 -18.72% | -21,4 | -22,6 | -23,8 | -24,9 | |
|
Net income Million USD | Released Forecast Spread | -13,9 -14,9 6.83% | -12,9 -15,1 14.31% | -12,9 -14,9 13.54% | -11,4 -13,9 17.67% | -15,7 -13,5 -16.67% | -15,9 -15,3 -3.75% | -14,5 -16,6 12.96% | -16,4 -17,0 3.12% | -20,9 -17,6 -18.72% | -21,4 | -22,6 | -23,8 | -24,9 | |
|
EPS USD | Released Forecast Spread | -0,49 -0,60 17.88% | -0,45 -0,52 13.88% | -0,45 -0,50 10.71% | -0,39 -0,48 19.03% | -0,52 -0,44 -18.18% | -0,45 -0,48 6.25% | -0,37 -0,45 17.25% | -0,37 -0,41 9.12% | -0,46 -0,39 -17.61% | -0,48 | -0,47 | -0,47 | -0,48 | -0,67 |
| Announcement Date | 17/03/22 | 12/05/22 | 11/08/22 | 10/11/22 | 16/03/23 | 11/05/23 | 10/08/23 | 09/11/23 | 21/03/24 | - | - | - | - | - |
| Today 04:01 pm | VERTEX PHARMACEUTICALS INCORPORATED: Q1 2024 Earnings Release |
| 2024-05-06 | COGENT BIOSCIENCES, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-05-06 | LYELL IMMUNOPHARMA, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-05-06 | Y-MABS THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-05-06 | INNOCARE PHARMA LIMITED: Q1 2024 Earnings Release (Projected) |
| 2024-05-06 | PHILOGEN S.P.A.: Q1 2024 Earnings Release |
| 2024-05-07 07:00 am | RHYTHM PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| 2024-05-07 07:00 am | MADRIGAL PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| 2024-05-07 04:01 pm | HALOZYME THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-05-07 | ANAPTYSBIO, INC.: Q1 2024 Earnings Release (Projected) |
Past sector events for Cabaletta Bio, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- CABA Stock
- Calendar Cabaletta Bio, Inc.